3 burning questions after big CRISPR patent ruling; White House shifts to more targeted Covid strategy

The patent ruling will complicate things for the flock of companies trying to commercialize CRISPR-based medicines. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

STAT+: 3 burning questions spurred by the big CRISPR patent ruling By Megan Molteni Adobe The patent decision could cost the losing side millions in licensing fees, a windfall that will instead land on the Broad’s doorstep. Read More As Omicron recedes, White House shifts to a more targeted Covid strategy By Lev Facher Anna Moneymaker/Getty Images The Omicron variant is receding, and Americans are returning to everyday life. But the White House isn't done with its Covid response. Read More In a defamation lawsuit, the hype around digital health clashes with scientific criticism By Kate Sheridan and Casey Ross Molly Ferguson for STAT A retraction often ends a scientific dispute. For a digital fertility tracker made by Valley Electronics, it was only the beginning. Read More Sponsor content by STAT Events The STAT Breakthrough Science Summit On March 31, take an inside look at the technologies and procedures set to redefine medicine, and change patient care in the years to come. You'll hear from the CEOs, scientists, entrepreneurs at the forefront of these efforts. Get your pass now, and use your STAT+ subscriber login to unlock a 20% discount. STAT+: Nevada joins a little-known, ambitious state consortium dedicated to better drug prices By Ed Silverman Adobe Nevada has joined a consortium formed by Oregon and Washington to pool purchasing power and get better prices on prescription drugs. Read More Organoids reveal the tipping point when kidney damage turns irreversible By Elizabeth Cooney N. Gupta, et al., Science Translational Medicine Researchers used the miniature models to find the juncture between kidney injury that is fixable and damage that's beyond repair. Read More STAT+: Aurinia Pharma's takeout hopes dim with new legal challenge to key drug patent By Adam Feuerstein Takeover speculation has swirled since late 2019 when the company's lead drug proved to be an effective treatment for lupus nephritis. Read More Opinion: Rediscovering a language of healing that doesn't require 'cure' By Lee D. Cooper Adobe Stopping a genetic disease in its tracks, and maybe even reversing its progression, is an extraordinary achievement. But it is seldom a cure. Read More Wednesday, March 2, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser